NATCO Pharma Second Quarter 2025 Earnings: Beats Expectations

NATCO Pharma (NSE:NATCOPHARM) Second Quarter 2025 Results

Key Financial Results

• Revenue: ₹14.3b (up 39% from 2Q 2024).
• Net income: ₹6.77b (up 84% from 2Q 2024).
• Profit margin: 47% (up from 36% in 2Q 2024). The increase in margin was driven by higher revenue.
• EPS: ₹37.81 (up from ₹20.60 in 2Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

NATCO Pharma Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 20%.

Looking ahead, revenue is expected to decline by 5.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in India are expected to grow by 11%.

Performance of the Indian Pharmaceuticals industry.

The company's shares are down 5.5% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with NATCO Pharma (at least 1 which makes us a bit uncomfortable), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.